Amgen (AMGN) Tops Q4 EPS by 56c, Beats on Revenue; Offers FY26 Guidance

Amgen (NASDAQ: AMGN) reported Q4 EPS of $5.29, $0.56 better than the analyst estimate of $4.73. Revenue for the quarter came in at $9.9 billion versus the consensus estimate of $9.46 billion.

GUIDANCE:

Amgen sees FY2026 EPS of $21.60-$23.00, versus the consensus of $22.10. Amgen sees FY2026 revenue of $37-38.4 billion, versus the consensus of $37.1 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• Pakistan's Sharif: Confirm That A Final, Agreed Text Reached
• Jefferies says Europe battery electric vehicle sales jump in May